5-((2-Chloro-4-nitro-5-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)amino)-1H-benzo[d]imidazol-2(3H)-one

ID: ALA4069588

Chembl Id: CHEMBL4069588

PubChem CID: 137638446

Max Phase: Preclinical

Molecular Formula: C18H17ClN4O5

Molecular Weight: 404.81

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=c1[nH]c2ccc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)cc2[nH]1

Standard InChI:  InChI=1S/C18H17ClN4O5/c19-12-8-16(23(25)26)17(28-11-3-5-27-6-4-11)9-14(12)20-10-1-2-13-15(7-10)22-18(24)21-13/h1-2,7-9,11,20H,3-6H2,(H2,21,22,24)

Standard InChI Key:  PLNHZWDKSADKGN-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4069588

    ---

Associated Targets(Human)

BCL6 Tchem BCoR-BCL6 (22 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 404.81Molecular Weight (Monoisotopic): 404.0887AlogP: 3.72#Rotatable Bonds: 5
Polar Surface Area: 122.28Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.88CX Basic pKa: CX LogP: 2.93CX LogD: 2.93
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.44Np Likeness Score: -1.20

References

1. Yasui T, Yamamoto T, Sakai N, Asano K, Takai T, Yoshitomi Y, Davis M, Takagi T, Sakamoto K, Sogabe S, Kamada Y, Lane W, Snell G, Iwata M, Goto M, Inooka H, Sakamoto JI, Nakada Y, Imaeda Y..  (2017)  Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.,  25  (17): [PMID:28760529] [10.1016/j.bmc.2017.07.037]

Source